Brain targeting of risperidone-loaded solid lipid nanoparticles by intranasal route

References

• Banks WA, Morley JE, Niehoff ML, Mattern C. (2009). Delivery of testosterone to the brain by intranasal administration: comparison to intravenous testosterone. J Drug Target, 17, 91–97.
   PubMed Web of Science ®Google Scholar
• Blasi P, Giovagnoli S, Schoubben A, Ricci M, Rossi C. (2007). Solid lipid nanoparticles for targeted brain drug delivery. Adv Drug Deliv Rev, 59, 454–477.
   PubMed Web of Science ®Google Scholar
• Bondì ML, Fontana G, Carlisi B, Giammona G. (2003). Preparation and characterization of solid lipid nanoparticles containing cloricromene. Drug Deliv, 10, 245–250.
   PubMed Web of Science ®Google Scholar
• Chow HS, Chen Z, Matsuura GT. (1999). Direct transport of cocaine from the nasal cavity to the brain following intranasal cocaine administration in rats. J Pharm Sci, 88, 754–758.
   PubMed Web of Science ®Google Scholar
• Dhuria SV, Hanson LR, Frey WH, 2nd. (2010). Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J Pharm Sci, 99, 1654–1673.
   PubMed Web of Science ®Google Scholar
• Doijad RC, Manvi FV, Godhwani DM, Joseph R, Deshmukh NV. (2008). Formulation and targeting efficiency of cisplatin engineered solid lipid nanoparticles. Indian J Pharm Sci, 70, 203–207.
   PubMed Web of Science ®Google Scholar
• Ellenbroek BA, Peeters BW, Honig WM, Cools AR. (1987). The paw test: a behavioural paradigm for differentiating between classical and atypical neuroleptic drugs. Psychopharmacology (Berl), 93, 343–348.
   PubMed Web of Science ®Google Scholar
• Ellenbroek BA, Zhang XX, Jin GZ. (2006). Effects of (−)stepholidine in animal models for schizophrenia. Acta Pharmacol Sin, 27, 1111–1118.
   PubMed Web of Science ®Google Scholar
• Huang G, Zhang N, Bi X, Dou M. (2008). Solid lipid nanoparticles of temozolomide: potential reduction of cardial and nephric toxicity. Int J Pharm, 355, 314–320.
   PubMed Web of Science ®Google Scholar
• http://www.drugs.com (Accessed on March 12, 2010).
   Google Scholar
• http://www.nlm.nih.gov/medlineplus/druginformation.html (Accessed on March 12, 2010).
   Google Scholar
• Illum L. (2003). Nasal drug delivery—possibilities, problems and solutions. J Control Release, 87, 187–198.
   PubMed Web of Science ®Google Scholar
• Illum L. (2000). Transport of drugs from the nasal cavity to the central nervous system. Eur J Pharm Sci, 11, 1–18.
   PubMed Web of Science ®Google Scholar
• Khan S, Patil K, Bobade N, Yeole P, Gaikwad R. (2010). Formulation of intranasal mucoadhesive temperature-mediated in situ gel containing ropinirole and evaluation of brain targeting efficiency in rats. J Drug Target, 18, 223–234.
   PubMed Web of Science ®Google Scholar
• Koziara JM, Lockman PR, Allen DD, Mumper RJ. (2003). In situ blood–brain barrier transport of nanoparticles. Pharm Res, 20, 1772–1778.
   PubMed Web of Science ®Google Scholar
• Kumar M, Misra A, Babbar AK, Mishra AK, Mishra P, Pathak K. (2008). Intranasal nanoemulsion based brain targeting drug delivery system of risperidone. Int J Pharm, 358, 285–291.
   PubMed Web of Science ®Google Scholar
• Lu W, Jiang W, Chen J, Yin M, Wang Z, Jiang X. (2008). Modulation of brain delivery and copulation by intranasal apomorphine hydrochloride. Int J Pharm, 349, 196–205.
   PubMed Web of Science ®Google Scholar
• Manjunath K, Venkateswarlu V. (2005). Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intradeodenal administration. J Control Release, 107, 215–228.
   PubMed Web of Science ®Google Scholar
• Mathison S, Nagilla R, Kompella UB. (1998). Nasal route for direct delivery of solutes to the central nervous system: fact or fiction? J Drug Target, 5, 415–441.
   PubMed Web of Science ®Google Scholar
• Mehnert W, Mäder K. (2001). Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev, 47, 165–196.
   PubMed Web of Science ®Google Scholar
• Mistry A, Stolnik S, Illum L. (2009). Nanoparticles for direct nose-to-brain delivery of drugs. Int J Pharm, 379, 146–157.
   PubMed Web of Science ®Google Scholar
• Müller RH, Mäder K, Gohla S. (2000). Solid lipid nanoparticles (SLN) for controlled drug delivery—a review of the state of the art. Eur J Pharm Biopharm, 50, 161–177.
   PubMed Web of Science ®Google Scholar
• Pietrowky R, Thieman A, Kern W, Fehm HL, Bern J. (1996). A nose–brain pathway for psychotropic peptides, evidence from a brain evolved potential study with cholecystokinin. Psychoneuroendocrinology, 21, 559–572.
   PubMed Web of Science ®Google Scholar
• Powell CM, Miyakawa T. (2006). Schizophrenia-relevant behavioral testing in rodent models: a uniquely human disorder? Biol Psychiatry, 59, 1198–1207.
   PubMed Web of Science ®Google Scholar
• Reger MA, Watson GS, Frey WH 2nd, Baker LD, Cholerton B, Keeling ML, Belongia DA, Fishel MA, Plymate SR, Schellenberg GD, Cherrier MM, Craft S. (2006). Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype. Neurobiol Aging, 27, 451–458.
   PubMed Web of Science ®Google Scholar
• Roland I, Piel G, Delattre L, Evrard B. (2003). Systematic characterization of oil-in-water emulsions for formulation design. Int J Pharm, 263, 85–94.
   PubMed Web of Science ®Google Scholar
• Saha GB. (1993a). Methods of radiolabeling. In: Physics and Radiobiology of Nuclear Medicine. Springer-Verlag, New York, pp. 100–106.
   Google Scholar
• Saha GB. (1993b). Fundamentals of Nuclear Pharmacy, Quality control of Radiopharmaceuticals. Springer-Verlag, New York, pp. 154–160.
   Google Scholar
• Souto EB, Mehnert W, Müller RH. (2006). Polymorphic behaviour of Compritol888 ATO as bulk lipid and as SLN and NLC. J Microencapsul, 23, 417–433.
   PubMed Web of Science ®Google Scholar
• Sussman N. (2002). Choosing an atypical antipsychotic. Int Clin Psychopharmacol, 17(Suppl. 3), S29–S33.
   PubMedGoogle Scholar
• Wang JS, Ruan Y, Taylor RM, Donovan JL, Markowitz JS, DeVane CL. (2004). The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by P-glycoprotein. Int J Neuropsychopharmacol, 7, 415–419.
   PubMed Web of Science ®Google Scholar
• Yang SC, Lu LF, Cai Y, Zhu JB, Liang BW, Yang CZ. (1999). Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J Control Release, 59, 299–307.
   PubMed Web of Science ®Google Scholar